TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07262619: EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tum

Sponsor: Eikon Therapeutics · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 160 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT07262619 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07262619 Rescue Dossier →